Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Tamoxifen (2):
Recent article
Tamoxifen
The Breast (19)2 2010
Abstract
Adjuvant tamoxifen reduces relapses and prolongs survival in patients with oestrogen sensitive breast cancer. Development of resistance is however common. Tamoxifen can be given for a maximum of five years; although the risk of recurrences remains high after this period. This review examines nine ra...
|
PMID: 20096578
PDF is available here.
PDF is available here.
| < More recent | Older article > |
European Journal of Pharmacology (629)1-3 2010
Abstract
We performed voltage-clamp experiments to directly investigate the effects of 4OH-tamoxifen on the repolarizing K(+) currents in adult mouse ventricular myocytes in order to determine whether the effects of tamoxifen on repolarization could be ascribed to 4OH-tamoxifen. K(+) currents were recorded b...
|
PMID: 20006599
PDF is available here.
PDF is available here.
Abstract
Injured carotid arteries showed marked neointimal hyperplasia, which was significantly inhibited among animals treated with thalidomide or tamoxifen: neointimal/media ratios of 1.4 +/- 0.4 versus 0.2 +/- 0.1 versus 0.4 +/- 0.2, for INJ, INJ + Thalid, and INJ + Tamox; respectively (P < .001). The end...
|
PMID: 20304198
PDF is available here.
PDF is available here.
Ginekologia polska (81)3 2010
Abstract
Our data suggests that ovarian cancer cells platinum-sensitivity are not linked with ER expressions. We claim the necessity of seeking some TAM predicting factors, using DNA microarrays....
|
PMID: 20486538
PDF is available here.
PDF is available here.
Abstract
We tested the feasibility, effectiveness, and cell specificity of inducible Cre-mediated gene recombination in the postnatal inner ear using mice that express an inducible form of Cre (CreER(T)) under the transcriptional control of the proteolipid protein (PLP) promoter. We assessed the pattern of t...
|
PMID: 19820996
PDF is available here.
PDF is available here.
Abstract
We previously reported that fulvestrant-induced ERalpha degradation depends on the interaction of ERalpha with cytokeratins 8 and 18 (CK8/CK18). Here we further investigate the role of these two cytokeratins in the antagonistic activity of the SERD. Using ER-responsive reporter assays, we demonstrat...
|
PMID: 20061804
PDF is available here.
PDF is available here.
Le infezioni in medicina : rivista periodica di eziologia, epidemiologia, diagnostica, clinica e terapia delle patologie infettive (18)1 2010
Abstract
In a follow-up a 74-year-old woman with breast cancer (clinical stage T4N1M0 at onset, treatment by surgical resection and tamoxifen) presented a combination of two distinct diseases in the lung: breast cancer metastasis and tuberculosis. A CT scan showed multiple pulmonary nodular lesions and in on...
|
PMID: 20424525
PDF is available here.
PDF is available here.
Abstract
Abstract
Bulletin du cancer (97)3 2010
Abstract
Tamoxifen is a prodrug mainly metabolized by the CY2D6 cytochrome. More than 80 variants of the CYP2D6 gene have been identified. They predict four different enzymatic phenotypes: ultra-rapid metabolizers (UM), extensive metabolizers (EM), intermediate metabolizers (IM) and poor metabolizers (PM). S...
|
PMID: 20123649
PDF is available here.
PDF is available here.
Abstract
Molecular and Cellular Endocrinology (315)1-2 2010
Abstract
We previously showed that unliganded ERbeta inhibits ERalpha-mediated proliferation of MCF-7 cells. We investigated if tamoxifen might have a potential negative effect on some breast cancer cells by blocking the effects of unliganded ERbeta on gene regulation. Gene expression profiles demonstrated t...
|
PMID: 19744542
PDF is available here.
PDF is available here.
Lab Animal (39)2 2010
Abstract
Abstract
A new study published in the Journal of Clinical Oncology has ascertained the efficacy of selective serotonin-reuptake inhibitors, serotonin and norepinephrine reuptake inhibitors and gabapentin to decrease menopausal hot flashes. Are these nonhormonal treatment options a viable alternative to hormo...
|
PMID: 20098445
PDF is available here.
PDF is available here.
Abstract
Abstract
Women with early-stage breast cancers that express estrogen and/or progesterone receptors benefit from adjuvant hormonal therapy with antiestrogen drugs. Five years of tamoxifen is the standard to which other approaches have been compared. In premenopausal women, a total of 5 years of adjuvant hormo...
|
PMID: 19952743
PDF is available here.
PDF is available here.
Cancer Treatment Reviews (36)1 2010
Abstract
The third-generation aromatase inhibitors (AIs), including anastrozole, exemestane and letrozole, have demonstrated improved efficacy versus tamoxifen for the adjuvant endocrine treatment of postmenopausal patients with hormone receptor-positive breast cancer. AIs can be used in several adjuvant end...
|
PMID: 19944537
PDF is available here.
PDF is available here.
Pharmacotherapy (30)2 2010
Abstract
Roux-en-Y gastric bypass is a gastric reduction duodenal switch with a combination of restrictive and malabsorptive procedures. It is the most common gastric bypass procedure performed in the United States. Malabsorption causing nutritional deficiencies does occur, yet a PubMed literature search (19...
|
PMID: 20099995
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.
Pharmaceutical Research (27)2 2010
Abstract
To determine the better liposomal formulation incorporating the active metabolite of tamoxifen, 4-hydroxy-tamoxifen (4HT) and the biological impact of 4HT-pH-gradient liposomes on response to in vivo treatment.
Several pegylated liposomes were formulated by varying th...
|
PMID: 20033476
PDF is available here.
PDF is available here.